Sanofi (NASDAQ:SNY) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts maintain a “Hold” consensus on Sanofi, with nine hold, three buy, two strong-buy and one sell rating among 15 brokerages. The average 12-month price target is $49.50.
• Sanofi reported quarterly EPS of $2.41 on $13.36 billion in revenue, up 16% year over year, while analysts expect full-year EPS of approximately $5.01.
• Shares opened at $44.84, near the 200-day moving average of $44.83, with a market capitalization of $108.71 billion; institutional investors own 14.03% of the stock.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $49.50.

Several brokerages have recently issued reports on SNY. Wall Street Zen lowered shares of Sanofi from a "buy" rating to a "hold" rating in a report on Sunday, August 9th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Finally, Weiss Ratings cut Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, August 3rd.

Sanofi Stock Performance

Shares of SNY stock opened at $44.84 on Friday. The stock has a 50-day moving average of $43.62 and a 200-day moving average of $44.83. Sanofi has a one year low of $40.89 and a one year high of $52.68. The stock has a market cap of $108.71 billion, a PE ratio of 23.48, a price-to-earnings-growth ratio of 1.39 and a beta of 0.35. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm's revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.24 EPS. As a group, sell-side analysts expect that Sanofi will post 5.01 earnings per share for the current year.

Institutional Trading of Sanofi

A number of large investors have recently bought and sold shares of SNY. Physician Wealth Advisors Inc. lifted its stake in Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock valued at $28,000 after buying an additional 379 shares in the last quarter. Western Wealth Management LLC bought a new stake in shares of Sanofi during the first quarter worth $29,000. Leonteq Securities AG raised its holdings in shares of Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company's stock worth $29,000 after acquiring an additional 297 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in shares of Sanofi during the third quarter worth $29,000. Finally, Palisade Asset Management LLC bought a new stake in Sanofi in the 3rd quarter valued at $30,000. 14.03% of the stock is owned by institutional investors.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source